Skip to main content
. 2012 Jan 19;8(1):e1002464. doi: 10.1371/journal.pgen.1002464

Figure 5. Neuropeptide processing mutations and .

Figure 5

The paralytic response to aldicarb treatment was analyzed in strains containing mutations that inactivate pro-neuropeptide processing enzymes (egl-3 PC2 and egl-21 CPE), or those inactivating RIC-7. The number of trials (∼20 animals/trial) is shown for each genotype. Values that differ significantly from wild type (*, p<0.01; **, p<0.001, Students t-test) are indicated. Error bars indicate SEM. Values that are not significantly different are indicated (ns).